$0.41
+0.05 (+14.14%)
Open$0.40
Previous Close$0.36
Day High$0.43
Day Low$0.39
52W High$2.17
52W Low$0.23
Volume—
Avg Volume287.5K
Market Cap6.30M
P/E Ratio—
EPS$-2.75
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+9,143.3% upside
Current
$0.41
$0.41
Target
$37.99
$37.99
$25.94
$37.99 avg
$62.46
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 38.00M | 30.11M | 257.5K |
| Net Income | -76,311,591 | -54,417,583 | -16,876 |
| Profit Margin | -200.8% | -190.8% | -6.6% |
| EBITDA | -76,750,780 | -57,771,365 | -21,131 |
| Free Cash Flow | — | — | -13,268 |
| Rev Growth | +26.2% | +26.2% | +2.0% |
| Debt/Equity | 0.08 | 0.08 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $297.62 | +0.90% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $471.71 | +0.77% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $170.77 | +0.61% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $546.90 | -0.02% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $953.25 | -0.64% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $159.85 | +0.00% | 7.7 | 20.98B |